Ironwood PharmaceuticalsIRWD
IRWD
About: Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Employees: 253
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
72,380% more call options, than puts
Call options by funds: $50.7M | Put options by funds: $70K
14% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 37
8% more capital invested
Capital invested by funds: $672M [Q3] → $727M (+$55M) [Q4]
1% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 76
1% more funds holding
Funds holding: 220 [Q3] → 222 (+2) [Q4]
0.48% more ownership
Funds ownership: 102.09% [Q3] → 102.57% (+0.48%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$0.70
4%
downside
Avg. target
$4.94
580%
upside
High target
$14
1,827%
upside
5 analyst ratings
2 positive
40%
3 neutral
60%
0 negative
0%
Wells Fargo Mohit Bansal 26% 1-year accuracy 7 / 27 met price target | 38%upside $1 | Equal-Weight Downgraded | 15 Apr 2025 |
Jefferies Amy Li 0% 1-year accuracy 0 / 1 met price target | 4%downside $0.70 | Hold Downgraded | 15 Apr 2025 |
Leerink Partners Faisal Khurshid 23% 1-year accuracy 3 / 13 met price target | 38%upside $1 | Market Perform Maintained | 14 Apr 2025 |
JMP Securities Roy Buchanan 17% 1-year accuracy 4 / 24 met price target | 1,827%upside $14 | Market Outperform Maintained | 30 Jan 2025 |
Craig-Hallum Chase Knickerbocker 35% 1-year accuracy 9 / 26 met price target | 1,001%upside $8 | Buy Maintained | 22 Jan 2025 |
Financial journalist opinion
Based on 6 articles about IRWD published over the past 30 days
Neutral
Zacks Investment Research
4 days ago
Ironwood Shares Tank on Regulatory Update for Apraglutide
Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.
Negative
Benzinga
4 days ago
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug
Ironwood Pharmaceuticals, Inc. IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intestinal failure.
Neutral
Business Wire
5 days ago
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that, based on a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial is needed to seek approval of apraglutide for patients with short bowel syndrome (SBS) with intestinal failure (IF) who are dependent on parenteral suppor.
Positive
Seeking Alpha
1 week ago
Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth
Ironwood Pharmaceuticals (IRWD) is undergoing a challenging transition with LINZESS but has promising growth potential with apraglutide for short bowel syndrome (SBS). Despite declining revenue, LINZESS remains the market leader, and Ironwood's restructuring efforts aim to streamline operations and focus on apraglutide. Apraglutide's strong clinical data and potential FDA approval could significantly boost Ironwood's revenue, positioning it as a key player in the SBS market.
Neutral
Business Wire
3 weeks ago
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (the “Company”) (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that it received a notification letter (the “Notice”) on March 21, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company's delay in filing its Annual Report on Form 10-K fo.
Neutral
Business Wire
3 weeks ago
Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund
SAN ANTONIO--(BUSINESS WIRE)--Ironwood Midstream Energy Partners III, LLC (Ironwood III) today announced it has secured a substantial equity commitment from Kayne Anderson Energy Infrastructure Fund, Inc. (KYN). Led by industry veteran Mike Williams, Ironwood III has a long-term operating strategy, focused on the acquisition, development, and operation of top-tier midstream assets in the most economic and desirable oil and gas producing regions in the United States. In conjunction with the equi.
Neutral
24/7 Wall Street
1 month ago
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
If you work in the biotech industry, you might know the name Alex Denner.
Negative
Zacks Investment Research
1 month ago
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.
Neutral
Seeking Alpha
1 month ago
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2024 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Greg Martini - Chief Financial Officer Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Jason Butler - Citizens JMP Matt Cowper - Leerink Partners David Amsellem - Piper Sandler Operator My name is Kathleen, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Fourth Quarter 2024 Investor Update Conference Call.
Negative
Zacks Investment Research
1 month ago
Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to break-even earnings per share a year ago.
Charts implemented using Lightweight Charts™